The effects of parathyroid hormone and alendronate alone or in combination in postmenopausal osteoporosis

New England Journal of Medicine

Volumn 349, Issue 13, 2003, Pages 1207-1215

  Black, Dennis M ^a   Greenspan, Susan L ^e   Ensrud, Kristine E ^c   Palermo, Lisa ^a   McGowan, Joan A ^d   Lang, Thomas F ^b   Garnero, Patrick ^e   Bouxsein, Mary L ^f   Bilezikian, John P ^g   Rosen, Clifford J ^h,i  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

^d NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES   (United States)

^e Beth Israel Deaconess Medical Center ^*

^f BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^g St Joseph Hospital ^*  (United States)

^h ST JOSEPH HOSPITAL   (United States)

ⁱ JACKSON LABORATORY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALENDRONIC ACID; CALCIUM ION; PARATHYROID HORMONE; TUMS; VITAMIN D; BIOLOGICAL MARKER; CALCIUM; COLLAGEN; COLLAGEN TYPE 1; COLLAGEN TYPE I TRIMERIC CROSS LINKED PEPTIDE; COLLAGEN TYPE I TRIMERIC CROSS-LINKED PEPTIDE; N PROPEPTIDE TYPE I COLLAGEN; N-PROPEPTIDE TYPE I COLLAGEN; PEPTIDE; PHOSPHOPEPTIDE; PROCOLLAGEN; URIC ACID;

ADULT; AGED; ARTICLE; BONE DENSITY; BONE TURNOVER; CALCIUM INTAKE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG POTENTIATION; DUAL ENERGY X RAY ABSORPTIOMETRY; FATIGUE; FEMALE; FEMUR NECK; HEADACHE; HIP; HORMONAL THERAPY; HUMAN; HYPERCALCEMIA; LIMB PAIN; MAJOR CLINICAL STUDY; NAUSEA; POSTMENOPAUSE OSTEOPOROSIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SPINE; VERTIGO; BLOOD; BONE REMODELING; DRUG COMBINATION; DRUG EFFECT; FRACTURE; LUMBAR VERTEBRA; MIDDLE AGED; MULTICENTER STUDY; NON-PROGRAMMATIC; PATHOLOGY; PATIENT COMPLIANCE; RADIODENSITOMETRY; RADIOGRAPHY; SUBCUTANEOUS DRUG ADMINISTRATION; URINE;

NON-PROGRAMMATIC;

AGED; AGED, 80 AND OVER; ALENDRONATE; BIOLOGICAL MARKERS; BONE DENSITY; BONE REMODELING; CALCIUM; COLLAGEN; COLLAGEN TYPE I; DENSITOMETRY, X-RAY; DRUG THERAPY, COMBINATION; FEMALE; FEMUR NECK; FRACTURES, BONE; HUMANS; INJECTIONS, SUBCUTANEOUS; LUMBAR VERTEBRAE; MIDDLE AGED; OSTEOPOROSIS, POSTMENOPAUSAL; PARATHYROID HORMONE; PATIENT COMPLIANCE; PEPTIDES; PHOSPHOPEPTIDES; PROCOLLAGEN; URIC ACID; VITAMIN D;

EID: 0141684971     PISSN: 00284793     EISSN: None     Source Type: Journal    
DOI: 10.1056/NEJMoa031975     Document Type: Article

References (24)

1. National Osteoporosis Foundation. Physician's guide to prevention and treatment of osteoporosis. Belle Mead, N.J.: Excerpta Medica, 1999.
2. Cranney A, Guyatt G, Griffith L, Wells G, Tugwell P, Rosen C. Meta-analyses of therapies for postmenopausal osteoporosis. IX. Summary of meta-analyses of therapies for postmenopausal osteoporosis. Endocr Rev 2002;23:570-8.
3. Genant HK, Cooper C, Poor G, et al. Interim report and recommendations of the World Health Organization Task-Force for Osteoporosis. Osteoporos Int 1999;10:259-64.
4. Black DM, Cummings SR, Karpf DB, et al. Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Lancet 1996;348:1535-41.
5. Cummings SR, Black DM, Thompson DE, et al. Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention Trial. JAMA 1998;280: 2077-82.
6. Harris ST, Watts NB, Genant HK, et al. Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. JAMA 1999;282:1344-52.
7. Cranney A, Wells G, Willan A, et al. Meta-analyses of therapies for postmenopausal osteoporosis. II. Meta-analysis of alendronate for the treatment of postmenopausal women. Endocr Rev 2002;23:508-16.
8. Cranney A, Tugwell P, Adachi J, et al. Meta-analyses of therapies for postmenopausal osteoporosis. III. Meta-analysis of risedronate for the treatment of postmenopausal osteoporosis. Endocr Rev 2002;23: 517-23.
9. Neer RM, Arnaud CD, Zanchetta JR, et al. Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med 2001;344:1434-41.
10. Orwoll ES, Scheele WH, Paul S, et al. The effect of teriparatide [human parathyroid hormone (1-34)] therapy on bone density in men with osteoporosis. J Bone Miner Res 2003;18:9-17.
11. Kurland ES, Cosman F, McMahon DJ, Rosen CJ, Lindsay R, Bilezikian JP. Parathyroid hormone as a therapy for idiopathic osteoporosis in men: effects on bone mineral density and bone markers. J Clin Endocrinol Metab 2000;85:3069-76.
12. Rittmaster RS, Bolognese M, Ettinger MP, et al. Enhancement of bone mass in osteoporotic women with parathyroid hormone followed by alendronate. J Clin Endocrinol Metab 2000;85:2129-34.
13. Lindsay R, Nieves J, Formica C, et al. Randomised controlled study of effect of parathyroid hormone on vertebral-bone mass and fracture incidence among postmenopausal women on oestrogen with osteoporosis. Lancet 1997;350:550-5.
14. Lane NE, Sanchez S, Modin GW, Genant HK, Pierini E, Arnaud CD. Parathyroid hormone treatment can reverse corticosteroid-induced osteoporosis: results of a randomized controlled clinical trial. J Clin Invest 1998;102:1627-33.
15. Cummings SR, Bates D, Black DM. Clinical use of bone densitometry: scientific review. JAMA 2002;288:1889-97. [Erratum, JAMA 2002;288:2825.]
16. Lang TF, Li J, Harris ST, Genant HK. Assessment of vertebral bone mineral density using volumetric quantitative CT. J Comput Assist Tomogr 1999;23:130-7.
17. Lang TF, Keyak JH, Heitz MW, et al. Volumetric quantitative computed tomography of the proximal femur: precision and relation to bone strength. Bone 1997;21: 101-8.
18. MedDRA (medical dictionary for regulatory activities). Reston, Va.: MedDKA Maintenance and Support Services Organization (MSSO). (Accessed September 2, 2003, at http: //www.meddramsso.com/newwebaug2001/meddramsso/meddra/index.htm.)
19. Burr DB, Hirano T, Turner CH, Hotchkiss C, Brommage R, Hock JM. Intermittently administered human parathyroid hormone (1-34) treatment increases intracortical bone turnover and porosity without reducing bone strength in the humerus of ovariectomized cynomolgus monkeys. J Bone Miner Res 2001;16:157-65.
20. Rehman Q, Lang TF, Arnaud CD, Modin GW, Lane NE. Daily treatment with parathyroid hormone is associated with an increase in vertebral cross-sectional area in postmenopausal women with glucocorticoid-induced osteoporosis. Osteoporos Int 2003;14:77-81.
21. Zanchetta JR, Bogado CE, Ferretti JL, et al. Effects of teriparatide [recombinant human parathyroid hormone (1-34)] on cortical bone in postmenopausal women with osteoporosis. J Bone Miner Res 2003;18:539-43.
22. Misof BM, Roschger P, Cosman F, et al. Effects of intermittent parathyroid hormone administration on bone mineralization density in iliac crest biopsies from patients with osteoporosis: a paired study before and after treatment. J Clin Endocrinol Metab 2003; 88:1150-6.
23. Dempster DW, Cosman F, Kurland ES, et al. Effects of daily treatment with parathyroid hormone on bone microarchitecture and turnover in patients with osteoporosis: a paired biopsy study. J Bone Miner Res 2001;16:1846-53.
24. Finkelstein JS, Hayes A, Hunzelman JL, Wyland BJ, Lee H, Neer RM. The effects of parathyroid hormone, alendronate, or both in men with osteoporosis. N Eng J Med 2003; 349:1216-26